PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PD PagerDuty, Inc.

未开盘 08-14 16:00:00 EDT

11.90

-0.19

-1.57%

盘后11.90

+0.000.00%

19:34 EDT

最高12.41	最低11.76	成交量118.49万
今开12.41	昨收12.09	日振幅5.38%
总市值9.18亿	流通市值8.28亿	总股本7,712万
成交额1,412万	换手率1.70%	流通股本6,958万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PD","market":"US","secType":"STK","nameCN":"PagerDuty, Inc.","latestPrice":11.9,"timestamp":1786737600000,"preClose":12.09,"halted":0,"volume":1184931,"hourTrading":{"tag":"盘后","latestPrice":11.9,"preClose":11.9,"latestTime":"19:34 EDT","volume":40161,"amount":477915.9,"timestamp":1786750446891,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01571546732837051,"floatShares":69584020,"shares":77122565,"eps":2.117667,"marketStatus":"未开盘","change":-0.19,"latestTime":"08-14 16:00:00 EDT","open":12.41,"high":12.41,"low":11.76,"amount":14119178.042771999,"amplitude":0.053763,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.117667,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1554955200000,"exchange":"NYSE","adjPreClose":12.09,"preHourTrading":{"tag":"盘前","latestPrice":12.2532,"preClose":12.09,"latestTime":"09:29 EDT","volume":2894,"amount":34854.244962,"timestamp":1786714197090,"change":0.1632,"changeRate":0.013499,"amplitude":0.032258},"postHourTrading":{"tag":"盘后","latestPrice":11.9,"preClose":11.9,"latestTime":"19:34 EDT","volume":40161,"amount":477915.9,"timestamp":1786750446891,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.1101587030287616,"impliedVol":0.8853,"impliedVolPercentile":0.6574},"requestUrl":"/m/hq/s/PD","defaultTab":"news","newsList":[{"id":"2658970199","title":"康方生物(09926)：依达方®(依沃西，PD-1/VEGF)第三个适应症上市申请获得国家药品监督管理局批准，用于一线治疗SQ-NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2658970199","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658970199?lang=zh_cn&edition=full","pubTime":"2026-08-12 21:01","pubTimestamp":1786539717,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康方生物 发布公告，由公司自主研发的全球首创双特异性抗体依达方联合化疗用于一线治疗晚期鳞状非小细胞肺癌的新药上市申请，已获得中国国家药品监督管理局批准上市。这是依沃西获批上市的第三个适应症。依沃西联合化疗一线治疗sq-NSCLC新适应症的获批上市，是基于依沃西联合化疗对比替雷利珠单抗联合化疗一线治疗晚期sq-NSCLC的随机、对照、多中心III期临床研究中获得的显著阳性结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KURE","LU0417516902.SGD","LU0561508036.HKD","LU1169590202.USD","BK1161","IE00B543WZ88.USD","LU2778985437.USD","IPOS","LU0348784397.USD","LU0348735423.USD","LU1961090484.USD","LU1169589451.USD","BK1574","LU0348827113.USD","PD","LU2476274308.USD","IE00B5MMRT66.SGD","LU0348767384.USD","LU1794554557.SGD","LU2488822045.USD","IE00BPRC5H50.USD","LU0417516571.SGD","LU0348825331.USD","LU2399975544.HKD","BK4023","09926","LU0634319403.HKD","LU0348766576.USD","LU1720050803.USD","LU0540923850.HKD","LU0348783233.USD","LU0417516738.SGD","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657904156","title":"把肿瘤变成“原位疫苗”!Replimune(REPL.US)溶瘤病毒闯过FDA，PD-1耐药黑色素瘤迎来新一代免疫重启方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2657904156","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657904156?lang=zh_cn&edition=full","pubTime":"2026-08-07 14:59","pubTimestamp":1786085956,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1169590202.USD","BK4585","LU1169589451.USD","BK4139","PD","BK4023","BK4588","REPL","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655490356","title":"复宏汉霖(02696)：注射用HLX43(靶向PD-L1抗体偶联药物)联合贝伐珠单抗联合或不联合化疗用于晚期/转移性实体瘤治疗的临床试验申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2655490356","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655490356?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:33","pubTimestamp":1785486809,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，注射用HLX43联合贝伐珠单抗联合或不联合化疗用于晚期/转移性实体瘤治疗的临床试验申请获国家药品监督管理局批准。HLX43是由本公司利用许可引进的新型DNA拓扑异构酶I抑制剂小分子毒素-肽链连接子与本公司自主研发的靶向PD-L1的抗体进行偶联开发的靶向PD-L1的抗体偶联药物，拟用于晚期/转移性实体瘤的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02696","HK0000306701.USD","IBBJ","IBBQ","HK0000165453.HKD","HK0000306685.HKD","PSYK","MDTX","BK4023","HK0000320223.HKD","LU1169589451.USD","LU1169590202.USD","BMED","PD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652298475","title":"无问芯穹夏立雪：随着跨集群异构PD分离架构规模化落地，推理成本仍有10倍下降空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2652298475","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652298475?lang=zh_cn&edition=full","pubTime":"2026-07-20 15:21","pubTimestamp":1784532097,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1169590202.USD","LU1169589451.USD","PD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652638792","title":"基石药业-B(02616)：ESMO 2026预告-更多临床数据进一步验证 CS2009(PD-1/VEGF/CTLA-4三特异性抗体)临床潜力与全球开发前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2652638792","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652638792?lang=zh_cn&edition=full","pubTime":"2026-07-20 08:06","pubTimestamp":1784505987,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B(02616)发布公告，公司核心资产之一CS2009(PD-1/VEGF/CTLA-4三特异性抗体)的临床研究成果成功入选2026年欧洲肿瘤内科学会(ESMO)年会，并将以两项快速口头报告的形式呈现，分别涵盖CS2009在晚期非小细胞肺癌(NSCLC)以及转移性结直肠癌(mCRC)患者中的I/II期临床试验数据。目前，相关摘要标题已在ESMO官网公布。需说明的是，摘要中所呈现的数据仅截至2026年4月，旨在符合大会递交期限之要求。基石药业将于2026年10月23日至26日在西班牙马德里召开的ESMO年会现场，展示数据截止日期更临近会议时间的临床研究结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02616","LU1169589451.USD","LU1169590202.USD","BK4023","PD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651348206","title":"科伦博泰生物(06990)：核心产品TROP2ADC芦康沙妥珠单抗(sac-TMT)联合帕博利珠单抗一线治疗PD-L1阴性局部晚期或转移性非鳞状非小细胞肺癌3期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2651348206","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651348206?lang=zh_cn&edition=full","pubTime":"2026-07-15 07:32","pubTimestamp":1784071939,"startTime":"0","endTime":"0","summary":"安全性方面，芦康沙妥珠单抗联合帕博利珠单抗的安全性特征与既往研究报告一致，未观察到新的安全性信号。目前，本公司已在中国开展9项注册性临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","LU1169590202.USD","LU0196878994.USD","BK1161","LU1169589451.USD","PD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651104260","title":"安捷伦PD-L1伴随诊断试剂获FDA批准，用于食管胃癌免疫治疗筛选","url":"https://stock-news.laohu8.com/highlight/detail?id=2651104260","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651104260?lang=zh_cn&edition=full","pubTime":"2026-07-14 22:38","pubTimestamp":1784039880,"startTime":"0","endTime":"0","summary":"安捷伦科技公司近日宣布，其PD-L1 IHC 28-8 pharmDx试剂盒已获得美国食品药品监督管理局的批准，可作为伴随诊断工具，用于识别可能适合接受免疫治疗的患者。该试剂盒现可正式用于评估食管鳞状细胞癌、胃癌、胃食管交界处癌及食管腺癌患者的PD-L1蛋白表达水平。　　安捷伦表示，此次获批有助于标准化相关癌症的免疫治疗患者筛选流程，支持全球临床医生做出更精准的治疗决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-14/doc-inihuxfu8357115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PD","BK4585","BK4588","LU1169590202.USD","BK4023","LU1169589451.USD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650907155","title":"恒瑞医药回应PD-1联合疗法在美延迟批准：未涉及产品临床研究数据问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2650907155","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650907155?lang=zh_cn&edition=full","pubTime":"2026-07-10 14:43","pubTimestamp":1783665784,"startTime":"0","endTime":"0","summary":"恒瑞医药回应PD-1联合疗法在美延迟批准：未涉及产品临床研究数据问题","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607103801735795.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607103801735795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064130708.USD","BK0028","LU1169589451.USD","BK0196","LU2495084118.USD","LU2543165471.USD","LU1655091616.SGD","LU0405327494.USD","BK0060","BK0183","LU1781817850.SGD","LU1997245094.SGD","01276","LU2328871848.SGD","LU2097828474.EUR","LU2580892789.USD","LU0359201885.HKD","LU1169590202.USD","LU0405327148.USD","LU0359202008.SGD","PD","BK0012","600276","BK0239","LU2097828805.USD","LU1580142542.USD","LU2289578879.USD","LU1328615791.USD","LU1820825898.SGD","LU1997244956.HKD","LU1997245177.USD","LU2097828631.EUR","LU1023057109.AUD","LU1064131003.USD","BK4023","LU0359201612.USD","LU2148510915.USD","LU2097828557.USD","LU1146622755.USD","LU2580892862.HKD","LU2488822045.USD","LU1969619763.USD","BK0188","LU1255011170.USD","BK1191","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648220025","title":"和誉-B(02256)附属与阿斯利康达成战略合作开展同类首创口服PD-L1抑制剂ABSK043联合泰瑞沙®治疗非小细胞肺癌的临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2648220025","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648220025?lang=zh_cn&edition=full","pubTime":"2026-07-02 08:06","pubTimestamp":1782950774,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，本公司的附属公司上海和誉生物医药科技有限公司宣布，与阿斯利康签署战略合作协议，共同推进一项新型靶免联合疗法治疗非小细胞肺癌的临床研究。该联合研究是一项多中心、开放的I/II期临床试验，旨在评估和誉医药自主研发的同类首创口服小分子PD-L1抑制剂 ABSK043联合阿斯利康第三代EGFR-TKI泰瑞沙 ，用于治疗EGFR突变合并PD-L1阳性的局部晚期或转移性NSCLC患者中的安全性和疗效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AZNH","PD","IE00B5MMRT66.SGD","LU1267930573.SGD","LU2456880835.USD","LU1169589451.USD","LU0708994859.HKD","IE00B3T34201.USD","LU2476274720.SGD","BK4023","BK4588","LU2237443549.SGD","LU2237443622.USD","LU2237443895.HKD","AZN","02256","LU0058720904.USD","LU2237443978.SGD","LU0310800379.SGD","BK4568","LU0289739699.SGD","LU2237443382.USD","LU2237443465.HKD","BK1161","LU2468319806.SGD","LU2476274308.USD","LU1829250122.USD","BK4007","LU0029864427.USD","LU2417539215.USD","LU0889565916.HKD","LU2236285917.USD","LU2778985437.USD","LU0109394709.USD","LU0320765992.SGD","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU1169590202.USD","LU0432979614.USD","LU0128525929.USD","LU2488822045.USD","LU2089984988.USD","BK4585","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642293703","title":"先声药业(02096)：SIM0689(PD-1/VEGF双特异性抗体)获国家药品监督管理局签发药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2642293703","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642293703?lang=zh_cn&edition=full","pubTime":"2026-06-12 21:02","pubTimestamp":1781269339,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)发布公告，集团自主研发的靶向PD-1/ VEGF的双特异性抗体SIM0689已获得中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书，拟开展晚期实体瘤的临床试验。SIM0689是一种同时靶向程序性死亡受体1(PD-1)和血管内皮生长因子(VEGF)特殊表位的双特异性抗体，通过解除肿瘤细胞免疫抑制和抗血管生成，发挥强效的抗肿瘤活性。在多种人源化小鼠药效模型中，SIM0689在低剂量即展现出优异的抗肿瘤疗效，整体药效显著优于同类型分子，提示其在多种实体瘤中有广泛的应用前景。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169590202.USD","BK1583","BK1191","02096","LU1169589451.USD","BK4023","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642407722","title":"西南证券：PD~(L)1经治后耐药困局不容忽视 2026年催化密集","url":"https://stock-news.laohu8.com/highlight/detail?id=2642407722","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642407722?lang=zh_cn&edition=full","pubTime":"2026-06-11 15:52","pubTimestamp":1781164329,"startTime":"0","endTime":"0","summary":"目前康方生物AK104联合普络西单抗(VEGFR2单抗)，取得了目前IO经治肺癌已披露研究数据中最长的OS，mOS=16.7mo。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260611/20260611152451_49256.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260611/20260611152451_49256.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453091.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0028","BK0012","BK0188","LU1169590202.USD","BK0276","BK4107","LU0210528500.USD","L","BK4023","LU1169589451.USD","LU2487616109.SGD","LU0053666078.USD","600369","BK4585","BK0183","PD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640437984","title":"港股异动 | 康方生物(09926)高开逾9% 依沃西联合化疗战胜PD-1联合化疗OS结果发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2640437984","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640437984?lang=zh_cn&edition=full","pubTime":"2026-06-01 09:24","pubTimestamp":1780277063,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物今日大幅高开，截至发稿，涨9.23%，报129港元，成交额3.62亿港元。消息面上，康方生物PD-1/VEGF双抗依沃西单抗联合化疗一线治疗晚期鳞状非小细胞肺癌的III期HARMONi-6研究于ASCO大会全体会议公布最新结果。与替雷利珠单抗联合化疗相比，依沃西组患者死亡风险下降34%，OS达到统计学显著性，两年生存率64.7% vs 48.6%。HARMONi-6共入组532例患者，中央型鳞癌占比约63%，PD-L1 TPS＜1%患者占39%，多部位转移、肝转移及脑转移患者占比约33.8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0540923850.HKD","LU0417516571.SGD","LU0348784397.USD","PD","IE00B5MMRT66.SGD","LU1169589451.USD","LU0561508036.HKD","LU2476274720.SGD","09926","BK4023","BK4588","LU0348827113.USD","LU0348767384.USD","LU0348735423.USD","LU0348766576.USD","LU0417516902.SGD","LU0417516738.SGD","LU0348783233.USD","BK1574","LU1720050803.USD","LU2476274308.USD","BK1161","LU1794554557.SGD","LU2778985437.USD","LU0634319403.HKD","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU2399975544.HKD","LU1169590202.USD","VXUS","LU1961090484.USD","LU2488822045.USD","LU0348825331.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639136988","title":"中国创新药迎高光！康方生物核心产品战胜PD-1联合化疗总生存期结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2639136988","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639136988?lang=zh_cn&edition=full","pubTime":"2026-05-31 21:16","pubTimestamp":1780233368,"startTime":"0","endTime":"0","summary":"5月31日，《每日经济新闻》记者注意到，在2026年美国临床肿瘤学会（ASCO）年会上，康方生物（HK09926，股价118.10港元，市值1088亿港元）PD-1/VEGF双抗依沃西联合化疗对比替雷利珠单抗联合化疗，一线治疗晚期鳞状非小细胞肺癌（sq-NSCLC）III期HARMONi-6/AK112-306研究的OS（总生存期）显著阳性结果揭晓。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605313755214061.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605313755214061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00B5MMRT66.SGD","LU0540923850.HKD","IE00BPRC5H50.USD","BK1161","BK4023","LU0348783233.USD","LU0348827113.USD","159992","IE00B543WZ88.USD","LU0417516738.SGD","LU0348766576.USD","PD","LU0348825331.USD","09926","LU1720050803.USD","LU0348784397.USD","LU1169590202.USD","LU0417516571.SGD","LU0634319403.HKD","LU2476274720.SGD","LU0348735423.USD","BK1574","LU2488822045.USD","LU2778985437.USD","LU2399975544.HKD","LU1169589451.USD","LU0348767384.USD","LU2476274308.USD","LU1961090484.USD","LU1794554557.SGD","LU0417516902.SGD","LU0561508036.HKD","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636022270","title":"维立志博-B(09887)：维利信™(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)治疗晚期肺外神经内分泌癌的III期临床研究获得CDE批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636022270","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636022270?lang=zh_cn&edition=full","pubTime":"2026-05-19 07:18","pubTimestamp":1779146304,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，中华人民共和国国家药品监督管理局药品审评中心已批准开展评价维利信联合含铂化疗作为一线治疗在晚期肺外神经内分泌癌患者中的确证性III期临床研究。该研究获批是基于奥帕替苏米单抗在Ib/II期概念验证性研究中所展现的突破性疗效与良好安全性。奥帕替苏米单抗已在肺外神经内分泌癌、非小细胞肺癌、小细胞肺癌及胆道癌四个适应症的注册性或II 期临床试验中展示出全球首创或同类最优潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443206.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","LU1169589451.USD","CDE","LU1223082519.USD","LU1223083913.SGD","BK4023","HK0000252152.HKD","PD","09887","HK0000252160.HKD","BK1161","HK0000500386.USD","BK4017","LU1169590202.USD","LU1223082196.USD","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630946589","title":"Incyte受益于PD-1抑制剂强劲需求，一季度业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2630946589","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630946589?lang=zh_cn&edition=full","pubTime":"2026-04-28 23:30","pubTimestamp":1777390200,"startTime":"0","endTime":"0","summary":"Incyte公布的2026年第一季度财报显示，得益于核心药物及癌症治疗组合的强劲需求，公司业绩超出了华尔街分析师的普遍预期。　　财报数据显示，Incyte本季度总收入实现了同比增长，主要驱动力来自其重磅药物以及与日本武田制药合作的资产。Incyte的核心产品销售增长显著，同时其他商业资产的专营权使用费收入也持续向好。　　基于第一季度的超预期表现，Incyte重申了其2026年全年的业绩指引，预计市场对其创新药物的需求将保持稳定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-28/doc-inhwapms8394113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4023","LU1169589451.USD","LU1169590202.USD","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629089166","title":"维立志博-B(09887)：维利信TM(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)于一线胃或胃食管结合部腺癌II期试验的首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2629089166","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2629089166?lang=zh_cn&edition=full","pubTime":"2026-04-21 16:46","pubTimestamp":1776761213,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，评价维利信TM(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)用于治疗一线局部晚期或转移性胃或胃食管结合部腺癌的II期临床研究首例患者已成功入组。本次开展的开放标签、多中心Ⅱ期临床研究由北京大学肿瘤医院沈琳教授牵头，正在全国多家医院同步推进。该试验旨在评价奥帕替苏米单抗用于治疗一线局部晚期或转移性胃或胃食管结合部腺癌患者的有效性和安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4585","BK4555","BK4588","BK4604","HK0000252152.HKD","HK0000252160.HKD","BK4099","TM","HK0000500386.USD","BK4023","LU1169589451.USD","LU1169590202.USD","09887","PD","03160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624933592","title":"三安光电(600703.SH)：用于车载的VCSEL、PD产品已实现小批量出货","url":"https://stock-news.laohu8.com/highlight/detail?id=2624933592","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2624933592?lang=zh_cn&edition=full","pubTime":"2026-04-01 18:27","pubTimestamp":1775039223,"startTime":"0","endTime":"0","summary":"格隆汇4月1日丨三安光电(600703.SH)在投资者互动平台表示，公司用于车载的VCSEL、PD产品已实现小批量出货，与头部新能源车企客户持续对接，以提升份额。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260401/32118972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1169590202.USD","BK0188","BK0196","LU1169589451.USD","BK0183","BK0012","BK0214","BK0141","600703","BK0187","BK0175","PD","BK4023","BK0070","BK0064","BK0108","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622858900","title":"基石药业-B(02616)公布PD-1/VEGF/CTLA-4三特异性抗体CS2009的最新临床进展及I/II期关键临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2622858900","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2622858900?lang=zh_cn&edition=full","pubTime":"2026-03-26 17:09","pubTimestamp":1774516159,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 公布公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的最新临床进展。在肺癌中展现强劲疗效：CS2009单药针对肺癌的I/II期初步疗效资料积极。截至2026年3月中旬，I期研究已共入组113例晚期实体瘤患者，中位元随访期约为6个月;II期研究已共入组85例患者。在TME中，PD-1和 CTLA-4的双重阻断作用通过与VEGFA的交联显著增强。同时，CS2009可优先结合PD-1和CTLA-4双阳性的肿瘤浸润T细胞，并最大程度上弱化对外周T细胞中CTLA-4调节通路的干扰。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","LU1169589451.USD","PD","BK1161","02616","BK4023","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621775502","title":"三安光电(600703.SH)：可提供用于800G光模块的CW光源、VCSEL、EML、PD、EMPD等激光器、探测器产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2621775502","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2621775502?lang=zh_cn&edition=full","pubTime":"2026-03-23 15:57","pubTimestamp":1774252622,"startTime":"0","endTime":"0","summary":"格隆汇3月23日丨三安光电(600703.SH)在投资者互动平台表示，公司可提供用于800G光模块的CW光源、VCSEL、EML、PD、EMPD等激光器、探测器产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260323/32090105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4187","LU1169590202.USD","BK0188","EMPD","BK0214","PD","LU1169589451.USD","LU0054578231.USD","BK0175","BK0028","BK0187","600703","BK0141","BK4091","BK4023","CW","EML","BK0064","BK0070","BK0012","BK0108","BK0183","BK0196","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620782400","title":"复宏汉霖(02696)：纳武利尤单抗生物类似药HLX18(重组抗PD-1人源化单克隆抗体注射液)用于多种实体瘤治疗的1期临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2620782400","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2620782400?lang=zh_cn&edition=full","pubTime":"2026-03-20 18:14","pubTimestamp":1774001646,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，本公司自主研发的纳武利尤单抗生物类似药HLX18用于多种实体瘤治疗的1期临床试验申请获国家药品监督管理局批准。部分肿瘤细胞的PD-1配体上调，通过这个通路信号传导可抑制激活的T细胞对肿瘤的免疫监视。2025年12月， HLX18于美国获许可开展用于多种实体瘤治疗的1期临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416649.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4023","02696","HK0000165453.HKD","HK0000320264.USD","LU1169590202.USD","LU1169589451.USD","HK0000306685.HKD","HK0000306701.USD","HK0000320223.HKD","BK1161","PD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pagerduty.com","stockEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.107},{"period":"3month","weight":0.7578},{"period":"6month","weight":0.7147},{"period":"1year","weight":-0.2313},{"period":"ytd","weight":-0.0923}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"PagerDuty, Inc.于2010年5月根据特拉华州法律成立。该公司及其全资子公司提供了一个数字运营管理平台，为现代数字业务管理紧急和关键任务工作（“PagerDuty平台”）。PagerDuty平台从几乎任何支持软件的系统或设备收集数据和数字信号，并利用先进的人工智能和强大的机器学习实时关联、处理、预测和补救事件和机会。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.011871},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.075547},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.032883},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.032585},{"month":5,"riseRate":0.375,"avgChangeRate":0.055631},{"month":6,"riseRate":0.625,"avgChangeRate":0.015298},{"month":7,"riseRate":0.625,"avgChangeRate":0.027655},{"month":8,"riseRate":0.625,"avgChangeRate":0.015138},{"month":9,"riseRate":0,"avgChangeRate":-0.114196},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.036422},{"month":11,"riseRate":0.571429,"avgChangeRate":0.021164},{"month":12,"riseRate":0.571429,"avgChangeRate":0.042574}],"exchange":"NYSE","name":"PagerDuty, Inc.","nameEN":"PagerDuty, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PagerDuty, Inc.,PD,PagerDuty, Inc.股票,PagerDuty, Inc.股票老虎,PagerDuty, Inc.股票老虎国际,PagerDuty, Inc.行情,PagerDuty, Inc.股票行情,PagerDuty, Inc.股价,PagerDuty, Inc.股市,PagerDuty, Inc.股票价格,PagerDuty, Inc.股票交易,PagerDuty, Inc.股票购买,PagerDuty, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}